Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517192 · ClinicalTrials.gov registry record · Phase 3
Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT00517192 is a Phase 3 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 40 participants.
The verdict
NCT00517192, a Phase 3 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
The objective of this study is to compare the efficacy and safety of Tipranavir/ritonavir (TPV/r, 500mg/200mg twice daily) to the safety and efficacy of Darunavir/ritonavir (DRV/r 600 mg /100 mg twice daily) in combination with investigator selected optimised background regimens in patients who are three-class (Nucleoside reverse transcriptase inhibitors (NRTI), Nonnucleoside reverse transcriptase inhibitors (NNRTI), and Protease inhibitor (PI)) treatment-experienced (a minimum of 3-months duration for each class) with resistance to more than one PI on the screening virtual phenotype resistance testing.
Interventions
- DRUG Ritonavir
- DRUG Darunavir
- DRUG Tipranavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00517192
The ClinicalTrials.gov registry entry for NCT00517192 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ritonavir is the first listed.
NCT00517192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00517192 about?
NCT00517192 is a clinical study titled "Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI". The objective of this study is to compare the efficacy and safety of Tipranavir/ritonavir (TPV/r, 500mg/200mg twice daily) to the safety and efficacy of Darunavir/ritonavir (DRV/r 600 mg /100 mg twice daily) in combination with investigator selected optimised background regimens in patients who are ...
What is the current status of trial NCT00517192?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2007-09.
What interventions are being tested in trial NCT00517192?
The interventions under investigation include: Ritonavir (DRUG), Darunavir (DRUG), Tipranavir (DRUG).
Who is sponsoring clinical trial NCT00517192?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.